Details
The goals of this analysis were to estimate rates of interstitial lung disease (ILD) among patients with inflammatory bowel disease (IBD) and IBD subtypes (Crohn's disease and ulcerative colitis) and among cohorts of IBD patients 1) without prior exposure to vedolizumab or natalizumab, 2) without prior exposure to vedolizumab or natalizumab but with prior exposure to other advanced IBD therapies, or 3) initiating other advanced IBD therapies in the Sentinel Distributed Database (SDD). The study period includes data from January 1, 2006 to April 30, 2023. We distributed this request to six Sentinel Data Partners on February 16, 2024.
The analytic package associated with this analysis can be found externally in Sentinel's Git Repository located here. The Git Repository serves as Sentinel's version control tracking system for analytic packages and technical documentation.